i like it.
( JUNO )
CAR-Ts, mmune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution
DD From Last Data:
11/14 CUPID data show that heart failure, which is a progressive disease, became stabilized in MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function significantly improved or remained the same while these parameters deteriorated substantiallywith patients treated with placebo and concurrent optimal drug and device therapy.The safety profile from thisstudy was very favorable, with no significant side-effects from MYDICAR® therapy
charts yahoo or stocktwits
Good Time To Buy ADXS - Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO
By Adam Feuerstein
NEW YORK (TheStreet) -- Aduro Biotech is expected to make its public markets debut Thursday with an initial public offering that will value the cancer immunotherapy developer at more than $1 billion. Advaxis(ADXS) competitor working on similar cancer drugs, sports a valuation roughly half as large. Advaxis is developing three immunotherapy products that pair listeria with different cancer targets -- human papillomavirus (HPV), prostate-specific antigen (PSA) and HER-2, often associated with breast cancer.
The company and Merck (MRK) are working together on a phase II study which combined ADXS-PSA and Keytruda in patients with metastatic prostate cancer. An Advaxis collaboration with AstraZeneca (AZN) involves a combination of ADXS-PSA with MEDI 4736 (an anti-PD-L1) in patients with head and neck cancer. Advaxis also has ongoing partnerships with the Gynecological Oncology Group andAratana Therapeutics.Advaxis will be presented data on its listeria-based cancer immunotherapy plaform at the American Association for Cancer Research (AACR) annual meeting taking place April 18 to 22.
no brainer buy